Cargando…
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/ https://www.ncbi.nlm.nih.gov/pubmed/37395271 http://dx.doi.org/10.1172/JCI170762 |
_version_ | 1785067112098693120 |
---|---|
author | Ozbay Kurt, Feyza Gul Lasser, Samantha Arkhypov, Ihor Utikal, Jochen Umansky, Viktor |
author_facet | Ozbay Kurt, Feyza Gul Lasser, Samantha Arkhypov, Ihor Utikal, Jochen Umansky, Viktor |
author_sort | Ozbay Kurt, Feyza Gul |
collection | PubMed |
description | Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy. |
format | Online Article Text |
id | pubmed-10313369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-103133692023-07-03 Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target Ozbay Kurt, Feyza Gul Lasser, Samantha Arkhypov, Ihor Utikal, Jochen Umansky, Viktor J Clin Invest Review Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy. American Society for Clinical Investigation 2023-07-03 /pmc/articles/PMC10313369/ /pubmed/37395271 http://dx.doi.org/10.1172/JCI170762 Text en © 2023 Ozbay Kurt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Ozbay Kurt, Feyza Gul Lasser, Samantha Arkhypov, Ihor Utikal, Jochen Umansky, Viktor Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title | Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title_full | Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title_fullStr | Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title_full_unstemmed | Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title_short | Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
title_sort | enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/ https://www.ncbi.nlm.nih.gov/pubmed/37395271 http://dx.doi.org/10.1172/JCI170762 |
work_keys_str_mv | AT ozbaykurtfeyzagul enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget AT lassersamantha enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget AT arkhypovihor enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget AT utikaljochen enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget AT umanskyviktor enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget |